- Sophie Arie
India’s highest court has rejected efforts by the Swiss drug firm Novartis to patent its anticancer drug imatinib mesilate (marketed as Glivec) in the latest in a series of rulings in favour of India’s generic drug industry.
After a seven year legal battle the Supreme Court ruled that the drug was only an updated version of an existing one and as such was not innovative enough to merit a patent.
The ruling is seen as a crucial victory for manufacturers of generic drugs in the battle for India’s large and fast growing market. It means that …